Designated pharmacy health insurance status and future development trend.docVIP

 PAGE \* MERGEFORMAT 8 Designated pharmacy health insurance status and future development trend The future of China’s drug stores, according to whether intervention to a new tide of health care reform can be divided into two categories, one is designated health care pharmacies, and the other category is non-Medicare designated pharmacies. First, Medicare does not store the core competitiveness of fixed-point At present, China’s health insurance designated pharmacies, in fact, the core competitiveness is not relying on qualifications obtained point can get enough traffic, revenue and sales profit. So their service skills, pharmacy services, etc. Most of no obvious advantage, also tend not formal, not a real state regulations by selling products within the essential medicines list. The future, as the deepening of the new medical reform, medical reform in accordance with the advance of the Government’s new arrangements for the end of 2010, primary health care institutions based medicine catalog product ratio is 60%, the end of 2012 will have reached 100%, based drugs in primary product directory medical unit is zero slip, the price has obvious advantages, coupled with Medicare in-depth, patient voice at the high and grass-roots community health agencies around in order to retain patients, primary care organizations are reimbursed for out-patient proportion of patients with the purchase of medicines is gradually improving, Guangzhou can be reimbursed 300 yuan per person per month, with zero slip, the designated pharmacies to any advantage. Second, the new fixed-point health reform pharmacy qualifications and policy constraints 1, the number can not be infinite. As the Government’s financial ability to pay and insurance coverage of city employees and residents of the restrictions, anywhere, full liberalization of health insurance policies are not designated pharmacy approval, present, most of the city are lower than the number of health insurance pharma